Endostart Appoints Christopher Rowland Chairman of the Company’s Board of Directors.
The growth of Italian medical device start-up Endostart continues with the appointment of Christopher Rowland, a global expert in the medical device industry, to Chairman of the company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220714005706/en/
Endostart is proud to announce the appointment of Chris Rowland as Chairman of the company’s Board of Directors. Chris is a well-known expert in the medical device industry global market and joins Endostart with over 30 years of experience in sales, product development, marketing, business development, and executive leadership in the US and abroad. His unrivalled experience and business competency will be crucial as we commercialize our innovative medical device to improve the colonoscopy experience for physicians, patients, and the entire health care system. (Photo: Business Wire)
With over 30 years of experience in positions of increasing responsibility in sales, product development, marketing, business development, and CEO leadership in the US and abroad, Chris brings an unrivaled experience and competency in a wide variety of clinical and commercial medical devices verticals, including gastroenterology, cardiology, urology, radiology, and peripheral vascular specialties.
His professional experience includes 17 years with Boston Scientific, ending as the Global VP of Marketing for the Endoscopy Division; he also served as President of Given Imaging Inc. (acquired by Covidien/MDT) and President/CEO of Neotract Inc. (acquired by Teleflex). Chris is also currently the President and CEO of Tricol Biomedical, a leader in hemostasis technology.
In his new role, Chris will work with and coordinate the Board of Directors for Endostart.
“With his long history of leadership and his expertise in the digestive endoscopy industry, Chris is the ideal Chairman of the Board for Endostart,” said Alessandro Tozzi, CEO and founder of Endostart. “We are certain that Chris will be a driving force in our success.”
“I am excited to support the investors and the leadership team of this dynamic company. I believe Endostart is poised for significant growth reflecting demand for its innovative products to enhance endoscopic performance,” said Mr. Rowland. “I look forward to helping Endostart maximize shareholder value and realize its commercial potential.”
The first product from Endostart is Endorail™, an innovative medical device aimed at facilitating completion of colonoscopy procedures using Magnetic Balloon Technology. This technology is designed to enhance endoscope performance and enable endoscopists to easily achieve quality standards. Endorail received a CE mark in 2019 and has been tested in a clinical setting. It is not yet cleared by the US Food and Drug Administration (FDA).
Founded in 2018, Endostart is focused on developing and manufacturing next-generation medical devices for gastrointestinal endoscopy. The company is ISO 13485 certified. It has an international board of directors and a strong medical advisory board. It recently announced a capital increase of €8.2M (USD $10M).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teckro Partners with Reforestation Non-profit “One Tree Planted”5.8.2022 15:04:00 CEST | Press release
Teckro, creator of the only digitally interconnected clinical trial platform for real-time decision-making at the point of patient care, today announced a partnership with One Tree Planted to support native reforestation in Ireland. Teckro will plant trees quarterly to celebrate new clinical research sites and studies live on the Teckro platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220805005165/en/ “Working with One Tree Planted aligns with Teckro’s ethos of making an impact in the world,” said Gary Hughes, co-founder and chief executive officer. “Digitally interconnected clinical trials are good for the environment with less paper and a reduced need for in-person monitoring visits. This partnership enables us to plant trees in recognition of the sustainable gains achieved with our platform.” Planting trees is one of the best ways to combat the damaging effects of climate change. Trees help clean the air we breath
SES to Participate in Upcoming Investor Conferences5.8.2022 13:45:00 CEST | Press release
SES AI Corporation (NYSE: SES), a global leader in the development and manufacturing of high-performance lithium-metal (Li-Metal) rechargeable batteries for electric vehicles (EVs) and other applications, today announced that management will participate and host one-on-one meetings at the following investor conferences. J.P. Morgan Auto Conference Date: August 9, 2022 Location: New York City Jefferies Industrials Conference Date: August 10, 2022 Location: New York City Baird Newly Public Company Virtual Access Day Date: August 17, 2022 Location: Virtual Piper Sandler Energy Transition Leaders Summit Date: August 18, 2022 Location: Aspen, CO Cowen Global Transportation & Sustainable Mobility Conference Date: September 8, 2022 Location: Virtual RBC Capital Markets Global Industrials Conference Date: September 12, 2022 Location: Las Vegas, NV About SES SES is a global leader in development and production of high-performance Li-Metal rechargeable batteries for electric vehicles (EVs) and o
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 20225.8.2022 07:00:00 CEST | Press release
Regulatory News: Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Share, until 11:59 p.m., Eastern time on Thursday 11 August 2022, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., Eastern time, on Monday 8 August 2022. All other terms and conditions of the tender offer remain unchanged. Each CVR represents the right to receive one or more payments in cash, of up to $1.00 per CVR, contingent upon the achievement of certain milestones upon the terms and subject to the conditions d
Kirin Holdings’ Long-term GHG Reduction Target Was Approved by the Science Based Targets *1 Initiative Based on Science-based Net-zero Targets5.8.2022 04:00:00 CEST | Press release
Kirin Holdings Company, Limited (Kirin Holdings) has been approved as the first world company in the food and beverage processing sector with science-based net-zero targets validated by SBTi*2 in July 2022. The Kirin Group’s long-term GHG reduction target , "realizing net-zero*3 GHG*4 emission from the entire value chain by 2050" set forth in the Kirin Group Environmental Vision 2050 was certified as a scientifically based goal consistent with the level of GHG emission reductions required by the Paris Agreement*5 . Kirin Holdings, with the aim of becoming " A global leader in CSV*6”, have declared our goal of achieving net-zero emissions by 2020 under the Kirin Group Environmental Vision 2050 and have formulated a roadmap for achieving the goal, which went into operation in January 2022. A sense of crisis was shared around the world on the issue of climate change in the wake of the 2015 Paris Agreement, the 2018 IPCC 1.5°C Special Report*7 reported that global warming from pre-industri
INNIO Announces Future Collaboration With B.Grimm Power to Explore New Thailand Power Plant Projects4.8.2022 16:00:00 CEST | Press release
INNIO announced today that it has signed a Memorandum of Understanding (MoU) with B.Grimm Power to collaborate on building new power plant projects in Thailand. B.Grimm has a long and successful history as a trailblazer in Thailand’s private power generation industry. The MoU lays out the framework for a collaboration of the two companies to build projects in the period 2022 to 2024 within the liquified natural gas (LNG) and natural gas segment. Within the MoU, INNIO and B.Grimm will explore the development of decentralized and highly efficient power plants. The two companies will focus on jointly developing the LNG and natural gas segment in Thailand with the possibility of future projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220804005413/en/ Dr. Olaf Berlien, President and CEO of INNIO, and Dr. Harald Link, Chairman of the Board of B.Grimm (Photo: Business Wire) Across Southeast Asia, Thailand serves as one of t